Jeffrey Adelglass

996 total citations
21 papers, 265 citations indexed

About

Jeffrey Adelglass is a scholar working on Otorhinolaryngology, Epidemiology and Physiology. According to data from OpenAlex, Jeffrey Adelglass has authored 21 papers receiving a total of 265 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Otorhinolaryngology, 7 papers in Epidemiology and 5 papers in Physiology. Recurrent topics in Jeffrey Adelglass's work include Pneumonia and Respiratory Infections (6 papers), Sinusitis and nasal conditions (6 papers) and Allergic Rhinitis and Sensitization (5 papers). Jeffrey Adelglass is often cited by papers focused on Pneumonia and Respiratory Infections (6 papers), Sinusitis and nasal conditions (6 papers) and Allergic Rhinitis and Sensitization (5 papers). Jeffrey Adelglass collaborates with scholars based in United States, Austria and Bulgaria. Jeffrey Adelglass's co-authors include C. Andrew DeAbate, Terry M. Jones, Cynthia L. Fowler, Cynthia Siu, James B. Kahn, Barbara A. Wiesinger, Gary Ruoff, Michael H. Gold, Mitchel P. Goldman and Kaveh Alizadeh and has published in prestigious journals such as SHILAP Revista de lepidopterología, Journal of Allergy and Clinical Immunology and Vaccine.

In The Last Decade

Jeffrey Adelglass

17 papers receiving 237 citations

Peers

Countries citing papers authored by Jeffrey Adelglass

Since Specialization

Citations

This map shows the geographic impact of Jeffrey Adelglass's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey Adelglass with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey Adelglass more than expected).

Fields of papers citing papers by Jeffrey Adelglass

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey Adelglass. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey Adelglass. The network helps show where Jeffrey Adelglass may publish in the future.

Co-authorship network of co-authors of Jeffrey Adelglass

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey Adelglass. A scholar is included among the top collaborators of Jeffrey Adelglass based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey Adelglass. Jeffrey Adelglass is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Vaccine efficacy of NVX-CoV2373 against SARS-CoV-2 infection in adolescents in the USA: an ancillary study to a phase 3, observer-blinded, randomised, placebo-controlled trial 2025 ·The Lancet Microbe ·Meagan E. Deming, Elizabeth R. Brown, Monica A. McArthur, Stephanie J. Schrag, Melissa Arvay, (unknown), Jacques Ravel, Jeffrey Adelglass, Brandon Essink, David B. Musante, Rebecca Maguire, Richard L. Gorman, Elizabeth Formentini, Robín Masón, Merlin L. Robb, Kathleen M. Neuzil, Rekha R. Rapaka, P. A. Wolff, Karen L. Kotloff, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	2
2	Safety and immunogenicity of Omicron protein vaccines in mRNA-vaccinated adolescents: A phase 3, randomised trial 2025 ·Journal of Infection ·Chijioke Bennett, Gordon Chau, Elizabeth Clayton, Laurence Chu, (unknown), (unknown), (unknown), Joyce S. Plested, Mingzhu Zhu, (unknown), Zhaohui Cai, Raj Kalkeri, (unknown), Katherine Clegg Smith, Susan Neal, Fernando Noriega, Raburn M. Mallory, Jeffrey Adelglass	0
3	Immunogenicity of adjuvanted recombinant SARS-CoV-2 spike protein vaccine after earlier mRNA vaccine doses 2025 ·Journal of Allergy and Clinical Immunology ·Jeffrey Adelglass, Paul A. Bradley, (unknown), Gordon Chau, Raj Kalkeri, (unknown), Mingzhu Zhu, Zhaohui Cai, (unknown), Joyce S. Plested, Raburn M. Mallory, Lisa M. Dunkle	0
4	Efficacy and Safety of LetibotulinumtoxinA in the Treatment of Moderate and Severe Glabellar Lines in Females 35 to 50 Years of Age: Post Hoc Analyses of the Phase 3 Clinical Study Data 2024 ·SHILAP Revista de lepidopterología ·Michael H. Gold, Susan C. Taylor, Daniel S. Mueller, Jeffrey Adelglass, Joely Kaufman‐Janette, Sue Ellen Cox, (unknown), Konstantin Frank, Mark S. Nestor	3
5	Immunogenicity and safety of NVX-CoV2373 as a booster: A phase 3 randomized clinical trial in adults 2023 ·Vaccine ·(unknown), Matthew Davis, Jeffrey Adelglass, (unknown), Gordon Chau, Shane Cloney-Clark, (unknown), Raj Kalkeri, (unknown), Joyce S. Plested, Mingzhu Zhu, Lisa M. Dunkle	5
6	Efficacy and Safety of Letibotulinumtoxin A in the Treatment of Glabellar Lines: A Randomized, Double-Blind, Multicenter, Placebo-Controlled Phase 3 Study 2022 ·Aesthetic Surgery Journal ·Daniel S. Mueller, (unknown), Jeffrey Adelglass, Sue Ellen Cox, Michael H. Gold, Joely Kaufman‐Janette, Mark S. Nestor, Susan C. Taylor, Konstantin Frank	10
7	The Second of Two One-Year, Multicenter, Open-Label, Repeat-Dose, Phase II Safety Studies of PrabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients 2021 ·Aesthetic Surgery Journal ·(unknown), Jeffrey Adelglass, Rui L. Avelar, Leslie Baumann, Kenneth Beer, Joel L. Cohen, Sue Ellen Cox, Steven Dayan, Jeffrey S. Dover, Jeanine Downie, Zoé Kececioglu Draelos, Mitchel P. Goldman, (unknown), John Joseph, Joely Kaufman‐Janette, Ronald L. Moy, Mark S. Nestor, Joel Schlessinger, Stacy Smith, Robert A. Weiss	6
8	Calcium Hydroxylapatite Dermal Filler for Treatment of Dorsal Hand Volume Loss: Results From a 12-Month, Multicenter, Randomized, Blinded Trial 2017 ·Dermatologic Surgery ·Mitchel P. Goldman, Amir Moradi, Michael H. Gold, Daniel P. Friedmann, Kaveh Alizadeh, Jeffrey Adelglass, Bruce Katz	31
9	Efficacy and safety of once-daily luliconazole 1% cream in patients ≥12 years of age with interdigital tinea pedis: a phase 3, randomized, double-blind,vehicle-controlled study. 2014 ·PubMed ·Michael Jarratt, Terry M. Jones, Jeffrey Adelglass, A Bucko, Richard Pollak, (unknown), Jason T. Olin, Leonard J. Swinyer	11
10	Lidocaine/tetracaine peel in topical anesthesia prior to laser-assisted hair removal: Phase-II and Phase-III study results 2012 ·Journal of Dermatological Treatment ·Tina S. Alster, Jerome M. Garden, Richard Fitzpatrick, Marta I. Rendon, (unknown), Jeffrey Adelglass	19
11	Acute bacterial maxillary sinusitis: time to symptom resolution and return to normal activities with moxifloxacin 2007 ·International Journal of Clinical Practice ·Patricia A. Johnson, Jeffrey Adelglass, Bruce Rankin, Rosalyn Sterling, Karen Keating, Alice Benson, Peter Pertel	3
12	Comparison of sparfloxacin and clarithromycin in the treatment of acute bacterial maxillary sinusitis 1999 ·Clinical Therapeutics ·Dan Henry, (unknown), Jeffrey Adelglass, W. Michael Scheid, (unknown), (unknown), George H. Talbot	15
13	Loracarbef versus clarithromyin in children with acute otitis media with effusion 1999 ·Clinical Therapeutics ·W M Gooch, Jeffrey Adelglass, Douglas K. Kelsey, Daniel N. Masica, Don Johns, (unknown)	7
14	Comparison of the Effectiveness of Levofloxacin and Amoxicillin‐Clavulanate for the Treatment of Acute Sinusitis in Adults 1999 ·Otolaryngology ·Jeffrey Adelglass, C. Andrew DeAbate, (unknown), Cynthia L. Fowler, (unknown), (unknown)	44
15	A Multicenter, Investigator‐Blinded, Randomized Comparison of Oral Levofloxacin and Oral Clarithromycin in the Treatment of Acute Bacterial Sinusitis 1998 ·Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy ·Jeffrey Adelglass, Terry M. Jones, Gary Ruoff, James B. Kahn, Barbara A. Wiesinger, (unknown), Cynthia Siu	41
16	Efficacy and tolerability of cefprozil versus amoxicillin/clavulanate for the treatment of adults with severe sinusitis 1998 ·Clinical Therapeutics ·Jeffrey Adelglass, (unknown), Robert L. Woods	8
17	Dose Ranging Study of Mometasone Furoate (Nasonex) in Seasonal Allergic Rhinitis 1997 ·Annals of Allergy Asthma & Immunology ·Edwin A. Bronsky, Donald W. Aaronson, Robert Berkowitz, Paul Chervinsky, David F. Graft, Harold B. Kaiser, (unknown), Robert A. Nathan, David S. Pearlman, Paul H. Ratner, Jeffrey Adelglass, (unknown), Julius van Bavel, Frank C. Hampel, W. Stricker, (unknown), Francis M. Cuss, K. B. Nolop	55
18	Intranasal therapy with once-daily triamcinolone acetonide aerosol versus twice-daily beclomethasone dipropionate aqueous spray in patients with perennial allergic rhinitis 1996 ·Current Therapeutic Research ·(unknown), Jeffrey Adelglass, Thomas B. Casale, Robert M. Cohen, Kraig W. Jacobson, William B. Klaustermeyer, Warren Pleskow, (unknown), D. Robert Webb	3
19	1021 A multicenter study of the taste of the once-daily antihistamine cetirizine in children with perennial allergic rhinitis 1996 ·Journal of Allergy and Clinical Immunology ·Jeffrey Adelglass	1
20	1005 Evaluation of safety and efficacy of dexacort™ turbinaire® (DEX) nasal spray in patients with perennial allergic rhinitis 1996 ·Journal of Allergy and Clinical Immunology ·(unknown), Jeffrey Adelglass, Jonathan Corren, (unknown), Howard M. Schanker, (unknown), Steven J. Siegel	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact